C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases

Relative findings and response to therapy

Evan Y. Yu, Mark Muzi, Joy A. Hackenbracht, Brian B. Rezvani, Jeanne Link, Robert Bruce Montgomery, Celestia S. Higano, Janet F. Eary, David A. Mankoff

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Purpose of the Report: This study tested the feasibility of C11-acetate (acetate) positron emission tomography (PET) imaging to assess response to therapy in men with bone metastatic prostate cancer and compared results for disease detection and response evaluation with F-18 fluorodeoxyglucose (FDG) PET. Materials and Methods Men with >3 prostate cancer bone metastases identified by Tc-99m methylene diphosphonate (MDP) bone scintigraphy and/or computed tomography were enrolled in a prospective study of serial acetate and FDG PET imaging. Patients were imaged before and 6 to 12 weeks after initial androgen deprivation therapy for new metastatic prostate cancer or first-line chemotherapy with docetaxel for castration-resistant prostate cancer. Qualitative assessment and changes in the tumor:normal uptake ratio were used to assess response by both acetate and FDG PET. In addition, the detection of bone metastases pretherapy was compared for acetate and FDG PET. Results: A total of 8 patients with documented bone metastases were imaged, of which 6 were imaged both pre- and post-therapy. Acetate PET detected bone metastases in all 8 patients, whereas FDG PET detected lesions in 6 of the 7 imaged patients. Acetate PET generally detected more metastases with a higher tumor:normal uptake ratio. Qualitative and quantitative assessments of post-treatment response correlated with composite clinical designations of response, stable disease, or progression in 6 of 6 and 5 of 6 by acetate and 4 of 5 and 3 of 5 by FDG PET, respectively. Conclusion: In this pilot study, results indicate that acetate PET holds promise for response assessment of prostate cancer bone metastases and is complementary to FDG PET in bone metastasis detection.

Original languageEnglish (US)
Pages (from-to)192-198
Number of pages7
JournalClinical Nuclear Medicine
Volume36
Issue number3
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Bone Neoplasms
Fluorodeoxyglucose F18
Positron-Emission Tomography
Prostatic Neoplasms
Acetates
Neoplasm Metastasis
Bone and Bones
Therapeutics
docetaxel
Technetium Tc 99m Medronate
Castration
Feasibility Studies
Radionuclide Imaging
Androgens
Disease Progression
Neoplasms
Tomography
Prospective Studies

Keywords

  • bone metastases
  • C11-acetate (acetate)
  • F-18 fluorodeoxyglucose (FDG)
  • positron emission tomography (PET)
  • prostate cancer
  • response

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases : Relative findings and response to therapy. / Yu, Evan Y.; Muzi, Mark; Hackenbracht, Joy A.; Rezvani, Brian B.; Link, Jeanne; Montgomery, Robert Bruce; Higano, Celestia S.; Eary, Janet F.; Mankoff, David A.

In: Clinical Nuclear Medicine, Vol. 36, No. 3, 03.2011, p. 192-198.

Research output: Contribution to journalArticle

Yu, EY, Muzi, M, Hackenbracht, JA, Rezvani, BB, Link, J, Montgomery, RB, Higano, CS, Eary, JF & Mankoff, DA 2011, 'C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: Relative findings and response to therapy', Clinical Nuclear Medicine, vol. 36, no. 3, pp. 192-198. https://doi.org/10.1097/RLU.0b013e318208f140
Yu, Evan Y. ; Muzi, Mark ; Hackenbracht, Joy A. ; Rezvani, Brian B. ; Link, Jeanne ; Montgomery, Robert Bruce ; Higano, Celestia S. ; Eary, Janet F. ; Mankoff, David A. / C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases : Relative findings and response to therapy. In: Clinical Nuclear Medicine. 2011 ; Vol. 36, No. 3. pp. 192-198.
@article{ff3cfa76159e45c780950faffc8e21ed,
title = "C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: Relative findings and response to therapy",
abstract = "Purpose of the Report: This study tested the feasibility of C11-acetate (acetate) positron emission tomography (PET) imaging to assess response to therapy in men with bone metastatic prostate cancer and compared results for disease detection and response evaluation with F-18 fluorodeoxyglucose (FDG) PET. Materials and Methods Men with >3 prostate cancer bone metastases identified by Tc-99m methylene diphosphonate (MDP) bone scintigraphy and/or computed tomography were enrolled in a prospective study of serial acetate and FDG PET imaging. Patients were imaged before and 6 to 12 weeks after initial androgen deprivation therapy for new metastatic prostate cancer or first-line chemotherapy with docetaxel for castration-resistant prostate cancer. Qualitative assessment and changes in the tumor:normal uptake ratio were used to assess response by both acetate and FDG PET. In addition, the detection of bone metastases pretherapy was compared for acetate and FDG PET. Results: A total of 8 patients with documented bone metastases were imaged, of which 6 were imaged both pre- and post-therapy. Acetate PET detected bone metastases in all 8 patients, whereas FDG PET detected lesions in 6 of the 7 imaged patients. Acetate PET generally detected more metastases with a higher tumor:normal uptake ratio. Qualitative and quantitative assessments of post-treatment response correlated with composite clinical designations of response, stable disease, or progression in 6 of 6 and 5 of 6 by acetate and 4 of 5 and 3 of 5 by FDG PET, respectively. Conclusion: In this pilot study, results indicate that acetate PET holds promise for response assessment of prostate cancer bone metastases and is complementary to FDG PET in bone metastasis detection.",
keywords = "bone metastases, C11-acetate (acetate), F-18 fluorodeoxyglucose (FDG), positron emission tomography (PET), prostate cancer, response",
author = "Yu, {Evan Y.} and Mark Muzi and Hackenbracht, {Joy A.} and Rezvani, {Brian B.} and Jeanne Link and Montgomery, {Robert Bruce} and Higano, {Celestia S.} and Eary, {Janet F.} and Mankoff, {David A.}",
year = "2011",
month = "3",
doi = "10.1097/RLU.0b013e318208f140",
language = "English (US)",
volume = "36",
pages = "192--198",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases

T2 - Relative findings and response to therapy

AU - Yu, Evan Y.

AU - Muzi, Mark

AU - Hackenbracht, Joy A.

AU - Rezvani, Brian B.

AU - Link, Jeanne

AU - Montgomery, Robert Bruce

AU - Higano, Celestia S.

AU - Eary, Janet F.

AU - Mankoff, David A.

PY - 2011/3

Y1 - 2011/3

N2 - Purpose of the Report: This study tested the feasibility of C11-acetate (acetate) positron emission tomography (PET) imaging to assess response to therapy in men with bone metastatic prostate cancer and compared results for disease detection and response evaluation with F-18 fluorodeoxyglucose (FDG) PET. Materials and Methods Men with >3 prostate cancer bone metastases identified by Tc-99m methylene diphosphonate (MDP) bone scintigraphy and/or computed tomography were enrolled in a prospective study of serial acetate and FDG PET imaging. Patients were imaged before and 6 to 12 weeks after initial androgen deprivation therapy for new metastatic prostate cancer or first-line chemotherapy with docetaxel for castration-resistant prostate cancer. Qualitative assessment and changes in the tumor:normal uptake ratio were used to assess response by both acetate and FDG PET. In addition, the detection of bone metastases pretherapy was compared for acetate and FDG PET. Results: A total of 8 patients with documented bone metastases were imaged, of which 6 were imaged both pre- and post-therapy. Acetate PET detected bone metastases in all 8 patients, whereas FDG PET detected lesions in 6 of the 7 imaged patients. Acetate PET generally detected more metastases with a higher tumor:normal uptake ratio. Qualitative and quantitative assessments of post-treatment response correlated with composite clinical designations of response, stable disease, or progression in 6 of 6 and 5 of 6 by acetate and 4 of 5 and 3 of 5 by FDG PET, respectively. Conclusion: In this pilot study, results indicate that acetate PET holds promise for response assessment of prostate cancer bone metastases and is complementary to FDG PET in bone metastasis detection.

AB - Purpose of the Report: This study tested the feasibility of C11-acetate (acetate) positron emission tomography (PET) imaging to assess response to therapy in men with bone metastatic prostate cancer and compared results for disease detection and response evaluation with F-18 fluorodeoxyglucose (FDG) PET. Materials and Methods Men with >3 prostate cancer bone metastases identified by Tc-99m methylene diphosphonate (MDP) bone scintigraphy and/or computed tomography were enrolled in a prospective study of serial acetate and FDG PET imaging. Patients were imaged before and 6 to 12 weeks after initial androgen deprivation therapy for new metastatic prostate cancer or first-line chemotherapy with docetaxel for castration-resistant prostate cancer. Qualitative assessment and changes in the tumor:normal uptake ratio were used to assess response by both acetate and FDG PET. In addition, the detection of bone metastases pretherapy was compared for acetate and FDG PET. Results: A total of 8 patients with documented bone metastases were imaged, of which 6 were imaged both pre- and post-therapy. Acetate PET detected bone metastases in all 8 patients, whereas FDG PET detected lesions in 6 of the 7 imaged patients. Acetate PET generally detected more metastases with a higher tumor:normal uptake ratio. Qualitative and quantitative assessments of post-treatment response correlated with composite clinical designations of response, stable disease, or progression in 6 of 6 and 5 of 6 by acetate and 4 of 5 and 3 of 5 by FDG PET, respectively. Conclusion: In this pilot study, results indicate that acetate PET holds promise for response assessment of prostate cancer bone metastases and is complementary to FDG PET in bone metastasis detection.

KW - bone metastases

KW - C11-acetate (acetate)

KW - F-18 fluorodeoxyglucose (FDG)

KW - positron emission tomography (PET)

KW - prostate cancer

KW - response

UR - http://www.scopus.com/inward/record.url?scp=79951563645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951563645&partnerID=8YFLogxK

U2 - 10.1097/RLU.0b013e318208f140

DO - 10.1097/RLU.0b013e318208f140

M3 - Article

VL - 36

SP - 192

EP - 198

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 3

ER -